Publications
Bosch R., Petrone M., Arends R., Vicini P., Sijbrands E.J. G., Hoefman S., Snelder N. Characterisation of cotadutide’s dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model. British Journal of Pharmacology, 2024 [Link to publication].
Sepp A., Muliaditan M. Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies. Mabs, 2024 [Link to publication].
Noort van M., Ruppert M., DeJongh J., Marostica E., Bosch R., Mešić E., Snelder N. Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development. CPT: Pharmacometrics & Systems Pharmacology 2024 [Link to publication].
Wu Y., Allegaert K., Flint R.B., GouloozeS.C., Välitalo P.A.J., Hoog de M., Mulla H., Sherwin C.M.T., Simons S.H.P., Krekels E.H.J., Knibbe C.A.J., Völler S. When will the Glomerular Filtration Rate in Former Preterm Neonates Catch up with Their Term Peers? Pharmaceutical Research 2024 [Link to publication].
Noort van M., Ruppert M. Two new user-friendly methods to assess pharmacometric parameter identifiability on categorical and continuous scales. CPT: Pharmacometrics & Systems Pharmacology, 2024 [Link to publication].
Bosch R, Sijbrands E.J.G, Snelder N. Quantification of the effect of GLP-1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model. CPT: Pharmacometrics & Systems Pharmacology, 2024 [Link to publication].
Admiraal M.M., Velseboer D.C., Tjabbes H., Vis P., Peeters-Scholte C., Horn J. Neuroprotection after cardiac arrest with 2-iminobiotin: a single center phase IIa study on safety, tolerability, and pharmacokinetics. Frontiers in Neurology 2023. [Link to publication ].
Goulooze S.C, Vis P., Krekels E.H.J., Knibbe C.A.J. Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses. Expert Review of Clinical Pharmacology 2023 [Link to publication].
Eissing T., Goulooze S.C., Berg van der P., Noort van M., Ruppert M., Snelder N., Garmann D., Lippert J., Heinig R., Brinker M., Heerspink H.J.L. Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD. Diabetes, Obesity and Metabolism 2023 [Link to publication].
Noort van M., Ruppert M., Goulooze S.C., Berg van den P., Snelder N., Heerspink H.J., Garmann D., Lippert J., Heinig R., Brinker M., Eissing T. From glomerular filtration rate to renal composite endpoint: an integrated time-to-event analysis of finerenone in phase 3 studies. PAGE 2023 [Link to publication]